Original ResearchSingle-nucleotide polymorphism in the 5-α-reductase gene (SRD5A2) is associated with increased prevalence of metabolic syndrome in chemotherapy-treated testicular cancer survivors☆
Introduction
Since the introduction of platinum-based chemotherapy, metastatic testicular cancer has become a curable disease and most testicular cancer patients have an excellent prognosis. However, long-term toxicity can undermine life after treatment of testicular cancer [1], [2]. Cardiovascular disease, e.g. myocardial infarction, is more prevalent in testicular cancer survivors in comparison with age-matched controls [3], [4]. Several studies have shown that testicular cancer survivors are prone to develop cardiovascular risk factors, often clustered in the metabolic syndrome, following orchidectomy and platinum-based chemotherapy [5], [6], [7], [8].
The metabolic syndrome comprises central obesity, dyslipidemia, hypertension and insulin resistance. Due to its pre-diabetic and pro-atherogenic characteristics, the metabolic syndrome forms a seedbed for cardiovascular disease. Studies in the general population have shown that low levels of testosterone are associated with metabolic syndrome [9], [10]. The relationship is probably bi-directional. On one hand, an increase in adipose tissue enhances aromatization of testosterone, thereby contributing to hypogonadism. On the other hand, testosterone and its more potent metabolite dihydrotestosterone have several regulatory functions in adipose tissue and lower levels of androgens may lead to adverse metabolic changes, such as central obesity and insulin resistance [11], [12]. Testosterone is also a vasoactive hormone, as well as a regulating factor in glucose and lipid metabolism [13], [14], [15].
Subclinical hypogonadism appears to be a prominent risk factor for the metabolic syndrome in testicular cancer survivors [16]. A substantial proportion of testicular cancer survivors have a deteriorated gonadal function after chemotherapy that may persist for >10 years [17], [18]. It is difficult to predict which cancer survivors would benefit from testosterone supplementation. In a recent study by Finkelstein et al. in which 198 healthy men received different amounts of testosterone, the authors concluded that the amount of testosterone required for maintaining lean mass, fat mass, strength, and sexual function varied widely in men and argued that more personalized approaches for treating hypogonadism are needed [19].
Genetic variations that result in functional changes in androgenic enzymes may explain why some patients are more at risk for hormonal or metabolic changes and may help identify patients that are more likely to benefit from interventions, like testosterone supplementation therapy. In a recent study by Aschim et al., it was shown that polymorphisms in genes involved in androgen metabolism may partially explain inter-individual differences in gonadal toxicity in testicular cancer survivors [20].
Functional single-nucleotide polymorphisms (SNPs) in steroid 5-α-reductase type II (SRD5A2) result in variations in enzymatic activity of 5-α-reductase type II, affecting the conversion of testosterone into dihydrotestosterone [21]. We investigated whether SNPs rs523349 (V89L) and rs9282858 (A49T) in SRD5A2 are associated with cardiometabolic status in testicular cancer survivors.
Section snippets
Study population
Patients belonged to a cohort of long-term survivors of metastatic non-seminomatous testicular cancer treated between 1977 and 2004 with platinum-based chemotherapy at University Medical Center Groningen [7]. The study population consisted of 173 patients (Fig. 1). Inclusion criteria were attained age <60 years and a follow-up duration of minimum 3 years and maximum 20 years. Because our aim was to investigate newly developed cardiovascular risk factors after therapy, exclusion criteria were
Study population characteristics
The basic characteristics of the study population are described in Table 1. Median age at start of chemotherapy and during the follow-up assessment was 28 and 37 years, respectively. Median follow-up of patients was 5 years (range 3–20). Metabolic syndrome was prevalent in 44 of 173 patients (25%), as reported previously by De Haas et al [7]. Prevalence of individual components of the metabolic syndrome and hormonal status are reported in Table 1. A cut-off value of total testosterone
Discussion
We found an association between SNP rs523349 in the gene SRD5A2 and the prevalence of the metabolic syndrome in testicular cancer survivors. Our findings suggest a role of impaired androgen metabolism in the etiology of the metabolic syndrome in testicular cancer patients after orchidectomy and cisplatin-based chemotherapy. The metabolic syndrome was present in 25% of the total testicular cancer survivor population studied, as reported earlier [7]. Patients with testosterone levels <15 nmol/l
Funding
This work was supported by the Dutch Cancer Society (04-3157; 09-4365).
Conflict of interest statement
None declared.
References (33)
- et al.
Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer
Ann Oncol
(2013) - et al.
Components of the metabolic syndrome in long-term survivors of testicular cancer
Ann Oncol
(2007) - et al.
Early development of the metabolic syndrome after chemotherapy for testicular cancer
Ann Oncol
(2013) - et al.
Androgen metabolism in adipose tissue: recent advances
Mol Cell Endocrinol
(2009) - et al.
The metabolic syndrome in cancer survivors
Lancet Oncol
(2010) - et al.
Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer
Eur Urol
(2003) - et al.
Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer
Eur J Cancer
(2004) Profiling steroid hormones and urinary steroids
J Chromatogr
(1986)- et al.
A sensitive, simple and robust LC-MS/MS method for the simultaneous quantification of seven androgen- and estrogen-related steroids in postmenopausal serum
J Steroid Biochem Mol Biol
(2014) - et al.
Testicular cancer survivorship: research strategies and recommendations
J Natl Cancer Inst
(2010)
Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer
J Clin Oncol
Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer
J Clin Oncol
The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer
J Clin Oncol
Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors
Br J Cancer
Testosterone, sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies
Int J Epidemiol
Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20–79
Eur Heart J
Cited by (8)
Genotypes of ANKK1 and DRD2 genes and risk of metabolic syndrome and its components: A cross-sectional study on Iranian women
2021, Obesity Research and Clinical PracticeCitation Excerpt :Among different introduced risk factors, genetic factor is one of the notable factors in MetS progress [5]. A growing body of evidence points to the association of MetS and its components with single-nucleotide polymorphisms (SNP) in different genes [6,7]. In the meanwhile, there are some evidence about the role of dopamine D2 receptor (DRD2) polymorphisms on some metabolic traits such as obesity [8,9].
Long-term toxicity of cisplatin in germ-cell tumor survivors
2017, Annals of OncologyCitation Excerpt :Survivors who were homozygous or heterozygous for SRD5A2 rs523349 had higher prevalence of metabolic syndrome compared with wild-type survivors (33% versus 19%, P = 0.032). The highest prevalence (66.7%) was observed in patients with testosterone levels <15 nmol/l and a variant genotype [65]. Lampe et al reported long-term infertility with oligospermia or azoospermia after cisplatin related to baseline sperm counts.
Clinical and genetic risk factors for adverse metabolic outcomes in north American testicular cancer survivors
2018, JNCCN Journal of the National Comprehensive Cancer Network
- ☆
Part of this manuscript was presented in a poster discussion at the annual meeting of the American Society of Clinical Oncology in Chicago, 2011.